《強生Johnson &ampamp Johnson（JNJ）2024年第四季度及全年業績報告「NYSE」（英文版）（22頁）.pdf》由會員分享，可在線閱讀，更多相關《強生Johnson &ampamp Johnson（JNJ）2024年第四季度及全年業績報告「NYSE」（英文版）（22頁）.pdf（22頁珍藏版）》請在三個皮匠報告上搜索。

1、For immediate release 2.0%3.0%/2.5%$90.9B$91.7B/$91.3B 2.5%3.5%/3.0%$89.2B$90.0B/$89.6B 0.5%1.5%/1.0%$10.75$10.95/$10.85 7.7%9.7%/8.7%$10.50$10.70/$10.60 5.2%7.2%/6.2%Johnson&Johnson and SubsidiariesSupplementary Sales Data(Unaudited;Dollars in Millions)Percent Change20242023TotalOperationsCurrency2

2、0242023TotalOperationsCurrencySales to customers bysegment of businessInnovative Medicine(1)U.S.8,977$8,079 11.1%11.1 -33,970$31,169 9.0%9.0 -International5,355 5,643 (5.1)(1.0)(4.1)22,994 23,590 (2.5)1.3 (3.8)14,332 13,722 4.4 6.1 (1.7)56,964 54,759 4.0 5.7 (1.7)Innovative Medicine excluding COVID-

3、19 Vaccine(1)U.S.8,977 8,079 11.1 11.1 -33,970 31,169 9.0 9.0 -International5,355 5,599 (4.4)(0.3)(4.1)22,796 22,473 1.4 5.5 (4.1)14,332 13,678 4.8 6.5 (1.7)56,766 53,642 5.8 7.5 (1.7)MedTech U.S.4,227 3,930 7.6 7.6 -16,332 15,275 6.9 6.9 -International3,961 3,743 5.8 7.6 (1.8)15,525 15,125 2.6 5.4

4、(2.8)8,188 7,673 6.7 7.6 (0.9)31,857 30,400 4.8 6.2 (1.4)U.S.13,204 12,009 10.0 10.0 -50,302 46,444 8.3 8.3 -International9,316 9,386 (0.7)2.5 (3.2)38,519 38,715 (0.5)2.9 (3.4)Worldwide22,520 21,395 5.3 6.7 (1.4)88,821 85,159 4.3 5.9 (1.6)U.S.13,204 12,009 10.0 10.0 -50,302 46,444 8.3 8.3 -Internati

5、onal9,316 9,342 (0.3)2.9 (3.2)38,321 37,598 1.9 5.5 (3.6)Worldwide excluding COVID-19 Vaccine(1)22,520$21,351 5.5%6.9 (1.4)88,623$84,042 5.5%7.0 (1.5)Note:Percentages have been calculated using actual,non-rounded figures and,therefore,may not recalculate precisely.(1)Refer to supplemental sales info

6、rmation schedulesFOURTH QUARTERTWELVE MONTHS Percent ChangeJohnson&Johnson and SubsidiariesSupplementary Sales Data(Unaudited;Dollars in Millions)Percent Change20242023TotalOperationsCurrency20242023TotalOperationsCurrencySales to customers bygeographic areaU.S.13,204$12,009 10.0%10.0 -50,302$46,444

7、 8.3%8.3 -Europe4,921 4,962 (0.8)(0.2)(0.6)20,212 20,410 (1.0)(0.6)(0.4)Western Hemisphere excluding U.S.1,135 1,166 (2.7)17.6 (20.3)4,714 4,549 3.6 20.4 (16.8)Asia-Pacific,Africa3,260 3,258 0.1 0.9 (0.8)13,593 13,756 (1.2)2.3 (3.5)International9,316 9,386 (0.7)2.5 (3.2)38,519 38,715 (0.5)2.9 (3.4)W

8、orldwide22,520$21,395 5.3%6.7 (1.4)88,821$85,159 4.3%5.9 (1.6)Johnson&Johnson and SubsidiariesSupplementary Sales Data(Unaudited;Dollars in Millions)Percent Change20242023TotalOperationsCurrency20242023TotalOperationsCurrencySales to customers bygeographic area(ex.COVID-19 Vaccine)U.S.*13,204$12,009

9、 10.0%10.0 -50,302$46,444 8.3%8.3 -Europe(1)4,921 4,918 0.10.7 (0.6)20,014 19,293 3.7 4.1 (0.4)Western Hemisphere excluding U.S.*1,135 1,166 (2.7)17.6 (20.3)4,714 4,549 3.6 20.4 (16.8)Asia-Pacific,Africa*3,260 3,258 0.1 0.9 (0.8)13,593 13,756 (1.2)2.3 (3.5)International9,316 9,342 (0.3)2.9 (3.2)38,3

10、21 37,598 1.9 5.5 (3.6)Worldwide22,520$21,351 5.5%6.9 (1.4)88,623$84,042 5.5%7.0 (1.5)Note:Percentages have been calculated using actual,non-rounded figures and,therefore,may not recalculate precisely.(1)Refer to supplemental sales information schedules*No COVID-19 Vaccine salesPercent ChangeFOURTH

11、QUARTERTWELVE MONTHSPercent ChangeFOURTH QUARTERTWELVE MONTHSJohnson&Johnson and SubsidiariesCondensed Consolidated Statement of Earnings(Unaudited;in Millions Except Per Share Figures)PercentPercentPercentIncreaseAmountto SalesAmountto Sales(Decrease)Sales to customers22,520$100.021,395$100.05.3Cos

12、t of products sold7,128 31.66,798 31.84.9Gross Profit15,392 68.414,597 68.25.4Selling,marketing and administrative expenses6,453 28.65,810 27.111.1Research and development expense5,298 23.54,480 20.918.3In-process research and development impairments17 0.1580.3Interest(income)expense,net(144)(0.6)(2

13、12)(1.0)Other(income)expense,net(161)(0.7)(421)(2.0)Restructuring42 0.256 0.3Earnings before provision for taxes on income3,887 17.34,826 22.6(19.5)Provision for taxes on income456 2.1694 3.3(34.3)Net earnings from Continuing Operations3,431$15.24,132$19.3(17.0)Net earnings/(loss)from Discontinued O

14、perations,net of tax-(83)Net earnings3,431$4,049$Net earnings per share(Diluted)from Continuing Operations1.41$1.70$(17.1)Net earnings/(loss)per share(Basic)from Discontinued Operations*-$(0.03)$Average shares outstanding(Diluted)2,427.12,430.7Effective tax rate from Continuing Operations11.7%14.4%A

15、djusted earnings from Continuing Operations before provision for taxes and net earnings(1)Earnings before provision for taxes on income from Continuing Operations5,421$24.16,237$29.2(13.1)Net earnings from Continuing Operations4,946$22.05,562$26.0(11.1)Net earnings per share(Diluted)from Continuing

16、Operations2.04$2.29$(10.9)Effective tax rate from Continuing Operations8.8%10.8%*Basic shares of 2,407.2 are used to calculate loss per share in the fourth quarter of 2023 as use of diluted shares when in a loss position would be anti-dilutive.(1)See Reconciliation of Non-GAAP Financial Measures.FOU

17、RTH QUARTER20242023Johnson&Johnson and SubsidiariesCondensed Consolidated Statement of Earnings(Unaudited;in Millions Except Per Share Figures)PercentPercentPercentIncreaseAmountto SalesAmountto Sales(Decrease)Sales to customers88,821$100.085,159$100.04.3Cost of products sold27,471 30.926,553 31.23.

18、5Gross Profit61,350 69.158,606 68.84.7Selling,marketing and administrative expenses22,869 25.721,512 25.26.3Research and development expense17,232 19.415,085 17.714.2In-process research and development impairments211 0.2313 0.4 Interest(income)expense,net(577)(0.6)(489)(0.6)Other(income)expense,net4

19、,694 5.36,634 7.8 Restructuring234 0.3489 0.6Earnings before provision for taxes on income16,687 18.815,062 17.710.8Provision for taxes on income2,621 3.01,736 2.151.0Net earnings from Continuing Operations14,066$15.813,326$15.65.6Net earnings from Discontinued Operations,net of tax-21,827 Net earni

20、ngs14,066$35,153$Net earnings per share(Diluted)from Continuing Operations5.79$5.20$11.3Net earnings per share(Diluted)from Discontinued Operations-$8.52$Average shares outstanding(Diluted)2,429.42,560.4Effective tax rate from Continuing Operations15.7%11.5%Adjusted earnings from Continuing Operatio

21、ns before provision for taxes and net earnings(1)Earnings before provision for taxes on income from Continuing Operations28,979$32.629,811$35.0(2.8)Net earnings from Continuing Operations24,242$27.325,409$29.8(4.6)Net earnings per share(Diluted)from Continuing Operations9.98$9.92$0.6Effective tax ra

22、te from Continuing Operations16.3%14.8%(1)See Reconciliation of Non-GAAP Financial Measures.TWELVE MONTHS20242023Johnson&Johnson and SubsidiariesReconciliation of Non-GAAP Financial Measures(Dollars in Millions Except Per Share Data)2024202320242023Net Earnings from Continuing Operations,after tax-a

23、s reported$3,431$4,132$14,066$13,326Pre-tax Adjustments Litigation related(16)1665,4507,152Intangible Asset Amortization expense1,1711,1484,5264,532COVID-19 Vaccine related costs 12310 100663 Restructuring related 262139269798Medical Device Regulation 34788 204311 Acquisition,integration and divesti

24、ture related 298 237 1,226 339 (Gains)/losses on securities(68)(435)306641IPR&D impairments17 58 211 313 Tax AdjustmentsTax impact on special item adjustments 4(80)75(2,135)(2,694)Tax legislation and other tax related61(56)1928 Adjusted Net Earnings from Continuing Operations,after tax$4,946$5,562$2

25、4,242$25,409Average shares outstanding(Diluted)2,427.12,430.72,429.42,560.4Adjusted net earnings per share from Continuing Operations(Diluted)$2.04$2.29$9.98$9.92Operational adjusted net earnings per share from Continuing Operations(Diluted)$2.05$9.99 Notes:1 COVID-19 Vaccine related costs include r

26、emaining commitments and obligations,including external manufacturingnetwork exit costs and required clinical trial expenses,associated with the Companys completion of its COVID-19 vaccinecontractual commitments which was completed in Q4 2024.234 The tax impact related to special item adjustments re

27、flects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings.Fourth QuarterTwelve Months EndedIn fiscal 2023,the company completed a prioritization of its research and development(R&D)investment within the Innovative Medicine segment t

28、o focus on the most promising medicines with the greatest benefit to patients.This resulted in the exit of certain programs within therapeutic areas.The R&D program exits are primarily in infectious diseases and vaccines including the discontinuation of its respiratory syncytial virus(RSV)adult vacc

29、ine program,hepatitis and HIV development.The restructuring expense of$102 million Q4 2024 YTD and$55 million in the fiscal fourth quarter of 2023($479 million Q4 2023 YTD)includes the termination of partnered and non-partnered program costs,asset impairments and asset divestments.This program was c

30、ompleted in Q4 2024.In fiscal 2023,the company initiated a restructuring program of its Orthopaedics franchise within the MedTech segment to streamline operations by exiting certain markets,product lines and distribution network arrangements.The restructuring expense of$60 million in the fiscal four

31、th quarter of 2024($167 million Q4 2024 YTD)and$84 million in the fiscal fourth quarter of 2023($319 million Q4 2023 YTD)primarily includes costs related to the market and product exits.replacement of the existing European Medical Devices Directive regulatory framework,and manufacturers of currently

32、 marketed medical devices were required to comply with EU MDR beginning in May 2021.The Company considers the adoption of EU MDR to be a significant one-time regulatory change and is not indicative of on-going operations.The Company has excluded only external third-party regulatory and consulting co

33、sts from its MedTech operating segments measures of profit and loss used for making operating decisions and assessing performance.The implementation was substantially completed as of Q4 2024,and ongoing costs will be reflected in MedTechs operating results beginning in 2025.Johnson&Johnson and Subsi

34、diariesReconciliation of Non-GAAP Financial MeasureInnovative MedicineMedTechTotalWW As Reported4.4%6.7%5.3%U.S.11.1%7.6%10.0%International(5.1)%5.8%(0.7)%WW Currency(1.7)(0.9)(1.4)U.S.-International(4.1)(1.8)(3.2)WW Operational6.1%7.6%6.7%U.S.11.1%7.6%10.0%International(1.0)%7.6%2.5%Shockwave(3.4)(

35、1.2)U.S.(5.1)(1.7)International(1.5)(0.6)All Other Acquisitions and Divestitures(A&D)0.20.40.2U.S.0.10.80.3International0.30.00.1WW Adjusted Operational Ex A&D6.3%4.6%5.7%U.S.11.2%3.3%8.6%International(0.7)%6.1%2.0%COVID-19 Vaccine0.40.2U.S.0.00.0International0.70.4WW Adjusted Operational Ex A&D&COV

36、ID-19 Vaccine6.7%4.6%5.9%U.S.11.2%3.3%8.6%International0.0%6.1%2.4%Adjusted Operational Sales GrowthFOURTH QUARTER 2024 ACTUAL vs.2023 ACTUALSegmentsNote:Percentages are based on actual,non-rounded figures and may not sumJohnson&Johnson and SubsidiariesReconciliation of Non-GAAP Financial MeasureInn

37、ovative MedicineMedTechTotalWW As Reported4.0%4.8%4.3%U.S.9.0%6.9%8.3%International(2.5)%2.6%(0.5)%WW Currency(1.7)(1.4)(1.6)U.S.-International(3.8)(2.8)(3.4)WW Operational5.7%6.2%5.9%U.S.9.0%6.9%8.3%International1.3%5.4%2.9%Shockwave(1.9)(0.7)U.S.(2.9)(1.0)International(0.8)(0.3)All Other Acquisiti

38、ons and Divestitures(A&D)0.10.40.2U.S.0.10.80.3International0.20.10.1WW Adjusted Operational Ex A&D5.8%4.7%5.4%U.S.9.1%4.8%7.6%International1.5%4.7%2.7%COVID-19 Vaccine1.81.1U.S.0.00.0International4.22.6WW Adjusted Operational Ex A&D&COVID-19 Vaccine7.6%4.7%6.5%U.S.9.1%4.8%7.6%International5.7%4.7%5

39、.3%Note:Percentages are based on actual,non-rounded figures and may not sumAdjusted Operational Sales GrowthTWELVE MONTHS 2024 ACTUAL vs.2023 ACTUALSegments REPORTED SALES vs.PRIOR PERIOD($MM)REPORTED SALES vs.PRIOR PERIOD($MM)FOURTH QUARTERTWELVE MONTHSINNOVATIVE MEDICINE SEGMENT(2)20242023Reported

40、Operational(1)Currency20242023ReportedOperational(1)CurrencyIMMUNOLOGYUS2,856$3,033 -5.9%-5.9%-11,355$11,539 -1.6%-1.6%-Intl1,383 1,562 -11.5%-6.5%-5.0%6,473 6,513 -0.6%4.0%-4.6%WW4,238 4,595 -7.8%-6.1%-1.7%17,828 18,052 -1.2%0.4%-1.6%REMICADEUS 231 294 -21.4%-21.4%-1,009 1,143 -11.7%-11.7%-US Expor

41、ts(3)9 35 -73.3%-73.3%-98 147 -33.0%-33.0%-Intl117 100 16.5%22.9%-6.4%497 549 -9.5%-5.0%-4.5%WW359 429 -16.5%-15.0%-1.5%1,605 1,839 -12.8%-11.4%-1.4%SIMPONI/SIMPONI ARIAUS262 258 1.3%1.3%-1,082 1,124 -3.8%-3.8%-Intl321 244 32.1%44.2%-12.1%1,108 1,073 3.3%13.2%-9.9%WW583 502 16.2%22.1%-5.9%2,190 2,19

42、7 -0.3%4.5%-4.8%STELARAUS1,699 1,786 -4.9%-4.9%-6,720 6,966 -3.5%-3.5%-Intl650 967 -32.7%-29.6%-3.1%3,641 3,892 -6.4%-3.3%-3.1%WW2,349 2,753 -14.7%-13.6%-1.1%10,361 10,858 -4.6%-3.4%-1.2%TREMFYAUS654 657 -0.6%-0.6%-2,443 2,147 13.7%13.7%-Intl295 252 16.9%21.7%-4.8%1,227 999 22.8%27.6%-4.8%WW949 910

43、4.2%5.6%-1.4%3,670 3,147 16.6%18.1%-1.5%OTHER IMMUNOLOGYUS0 2 *-3 11 -74.1%-74.1%-Intl0 0 -0 0 -WW0 2 *3 11 -74.1%-74.1%-INFECTIOUS DISEASESUS331 353 -6.4%-6.4%-1,354 1,500 -9.8%-9.8%-Intl443 498 -11.2%-9.8%-1.4%2,042 2,918 -30.0%-29.3%-0.7%WW774 852 -9.2%-8.4%-0.8%3,396 4,418 -23.1%-22.7%-0.4%COVID

44、-19 VACCINEUS0 0 -0 0 -Intl0 44 *198 1,117 -82.4%-82.4%0.0%WW0 44 *198 1,117 -82.4%-82.4%0.0%EDURANT/rilpivirineUS7 9 -10.1%-10.1%-31 35 -10.0%-10.0%-Intl315 299 5.0%5.6%-0.6%1,241 1,115 11.2%11.2%0.0%WW322 307 4.6%5.1%-0.5%1,272 1,150 10.6%10.6%0.0%PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZAUS321 341 -5.8%

45、-5.8%-1,311 1,446 -9.4%-9.4%-Intl86 98 -12.9%-8.9%-4.0%401 408 -1.7%1.1%-2.8%WW407 439 -7.4%-6.5%-0.9%1,712 1,854 -7.7%-7.1%-0.6%OTHER INFECTIOUS DISEASESUS1 4 -53.1%-53.1%-11 19 -41.0%-41.0%-Intl43 58 -24.2%-22.4%-1.8%203 278 -26.7%-23.9%-2.8%WW45 62 -26.1%-24.4%-1.7%214 297 -27.6%-25.0%-2.6%Change

46、%ChangeREPORTED SALES vs.PRIOR PERIOD($MM)REPORTED SALES vs.PRIOR PERIOD($MM)FOURTH QUARTERTWELVE MONTHS20242023ReportedOperational(1)Currency20242023ReportedOperational(1)CurrencyNEUROSCIENCEUS1,148 1,022 12.3%12.3%-4,398 4,065 8.2%8.2%-Intl628 780 -19.6%-16.8%-2.8%2,718 3,076 -11.6%-7.8%-3.8%WW1,7

47、75 1,801 -1.5%-0.3%-1.2%7,115 7,140 -0.4%1.3%-1.7%CONCERTA/MethylphenidateUS33 39 -12.8%-12.8%-134 230 -41.7%-41.7%-Intl125 142 -11.5%-7.7%-3.8%507 554 -8.4%-4.1%-4.3%WW159 180 -11.7%-8.8%-2.9%641 783 -18.1%-15.1%-3.0%INVEGA SUSTENNA/XEPLION/INVEGA TRINZA/TREVICTAUS796 733 8.6%8.6%-3,125 2,897 7.9%7

48、.9%-Intl267 278 -4.0%-1.8%-2.2%1,097 1,218 -9.9%-7.1%-2.8%WW1,063 1,011 5.1%5.7%-0.6%4,222 4,115 2.6%3.4%-0.8%SPRAVATOUS269 180 50.1%50.1%-929 589 57.8%57.8%-Intl28 26 7.1%12.5%-5.4%148 100 48.2%51.2%-3.0%WW297 206 44.6%45.3%-0.7%1,077 689 56.4%56.8%-0.4%OTHER NEUROSCIENCEUS49 71 -31.0%-31.0%-210 34

49、9 -39.8%-39.8%-Intl206 334 -38.1%-35.4%-2.7%965 1,204 -19.8%-15.1%-4.7%WW255 404 -36.9%-34.6%-2.3%1,175 1,553 -24.3%-20.7%-3.6%ONCOLOGYUS3,019 2,285 32.2%32.2%-10,854 8,462 28.3%28.3%-Intl2,476 2,334 6.1%10.6%-4.5%9,926 9,199 7.9%12.1%-4.2%WW5,497 4,618 19.0%21.3%-2.3%20,781 17,661 17.7%19.8%-2.1%CA

50、RVYKTIUS304 145 *-869 469 85.2%85.2%-Intl31 13 *94 30 *WW334 159 *963 500 92.7%92.7%0.0%DARZALEXUS1,799 1,395 28.9%28.9%-6,588 5,277 24.8%24.8%-Intl1,285 1,155 11.3%17.0%-5.7%5,082 4,467 13.8%19.1%-5.3%WW3,084 2,550 20.9%23.5%-2.6%11,670 9,744 19.8%22.2%-2.4%ERLEADAUS342 287 19.0%19.0%-1,282 1,065 2

51、0.3%20.3%-Intl442 361 22.4%25.7%-3.3%1,717 1,322 29.8%32.9%-3.1%WW784 647 20.9%22.7%-1.8%2,999 2,387 25.6%27.3%-1.7%IMBRUVICAUS250 255 -2.0%-2.0%-1,020 1,051 -3.0%-3.0%-Intl481 533 -9.6%-6.8%-2.8%2,018 2,214 -8.8%-6.3%-2.5%WW731 788 -7.2%-5.2%-2.0%3,038 3,264 -6.9%-5.2%-1.7%TECVAYLIUS108 102 5.6%5.6

52、%-418 334 25.3%25.3%-Intl38 24 59.9%71.6%-11.7%131 61 *WW146 126 15.8%18.0%-2.2%549 395 38.8%39.8%-1.0%ZYTIGA/abiraterone acetateUS9 9 -7.3%-7.3%-34 50 -32.2%-32.2%-Intl127 191 -33.6%-30.7%-2.9%597 837 -28.6%-24.6%-4.0%WW135 201 -32.4%-29.6%-2.8%631 887 -28.8%-25.0%-3.8%OTHER ONCOLOGYUS208 90 *-643

53、215 *-Intl74 58 25.5%30.6%-5.1%288 269 7.1%10.4%-3.3%WW282 148 90.4%92.4%-2.0%931 484 92.5%94.3%-1.8%Change%ChangeREPORTED SALES vs.PRIOR PERIOD($MM)REPORTED SALES vs.PRIOR PERIOD($MM)FOURTH QUARTERTWELVE MONTHS20242023ReportedOperational(1)Currency20242023ReportedOperational(1)CurrencyPULMONARY HYP

54、ERTENSIONUS819 733 11.6%11.6%-3,143 2,697 16.5%16.5%-Intl274 282 -3.2%1.2%-4.4%1,140 1,117 2.0%8.2%-6.2%WW1,092 1,017 7.4%8.7%-1.3%4,282 3,815 12.3%14.1%-1.8%OPSUMITUS385 368 4.8%4.8%-1,520 1,292 17.7%17.7%-Intl160 169 -5.2%-2.5%-2.7%664 681 -2.4%1.1%-3.5%WW545 536 1.7%2.5%-0.8%2,184 1,973 10.7%11.9

55、%-1.2%UPTRAVIUS391 348 12.3%12.3%-1,511 1,326 13.9%13.9%-Intl75 70 5.7%11.2%-5.5%307 255 20.1%27.3%-7.2%WW465 419 11.2%12.1%-0.9%1,817 1,582 14.9%16.1%-1.2%OTHER PULMONARY HYPERTENSIONUS42 18 *-112 79 41.8%41.8%-Intl40 45 -10.0%-0.4%-9.6%169 182 -6.9%8.2%-15.1%WW82 61 32.3%39.3%-7.0%281 260 7.9%18.3

56、%-10.4%CARDIOVASCULAR/METABOLISM/OTHERUS805 652 23.3%23.3%-2,866 2,906 -1.4%-1.4%-Intl153 185 -17.6%-15.1%-2.5%696 765 -9.1%-7.1%-2.0%WW957 837 14.3%14.8%-0.5%3,562 3,671 -3.0%-2.6%-0.4%XARELTOUS676 525 28.5%28.5%-2,373 2,365 0.3%0.3%-Intl-WW676 525 28.5%28.5%-2,373 2,365 0.3%0.3%-OTHERUS130 127 1.5

57、%1.5%-494 541 -8.8%-8.8%-Intl153 185 -17.6%-15.1%-2.5%696 765 -9.1%-7.1%-2.0%WW281 312 -9.8%-8.3%-1.5%1,189 1,306 -8.9%-7.8%-1.1%TOTAL INNOVATIVE MEDICINEUS8,977 8,079 11.1%11.1%-33,970 31,169 9.0%9.0%-Intl5,355 5,643 -5.1%-1.0%-4.1%22,994 23,590 -2.5%1.3%-3.8%WW14,332$13,722$4.4%6.1%-1.7%56,964$54,

58、759 4.0%5.7%-1.7%See footnotes at end of schedule%Change%ChangeREPORTED SALES vs.PRIOR PERIOD($MM)REPORTED SALES vs.PRIOR PERIOD($MM)FOURTH QUARTERTWELVE MONTHSMEDTECH SEGMENT(2)20242023ReportedOperational(1)Currency20242023ReportedOperational(1)CurrencyCARDIOVASCULAR(4)US1,221$971 25.8%25.8%-4,513$

59、3,633 24.2%24.2%-Intl841 698 20.6%22.0%-1.4%3,194 2,717 17.6%20.9%-3.3%WW2,062 1,669 23.6%24.2%-0.6%7,707 6,350 21.4%22.8%-1.4%ELECTROPHYSIOLOGYUS681 667 2.1%2.1%-2,738 2,458 11.4%11.4%-Intl640 572 11.7%13.3%-1.6%2,529 2,230 13.4%17.0%-3.6%WW1,321 1,239 6.6%7.3%-0.7%5,267 4,688 12.3%14.0%-1.7%ABIOME

60、DUS308 276 11.3%11.3%-1,213 1,066 13.7%13.7%-Intl77 64 19.8%21.1%-1.3%284 240 18.2%20.3%-2.1%WW384 340 12.9%13.2%-0.3%1,496 1,306 14.5%14.9%-0.4%SHOCKWAVE(5)US202 -*-442 -*-Intl56 -*-122 -*-WW258 -*-564 -*-OTHER CARDIOVASCULAR(4)US31 28 11.1%11.1%-120 109 10.7%10.7%-Intl68 61 12.1%12.3%-0.2%260 247

61、5.3%7.3%-2.0%WW99 89 11.8%12.0%-0.2%380 356 6.9%8.4%-1.5%ORTHOPAEDICSUS 1,460 1,425 2.4%2.4%-5,689 5,525 3.0%3.0%-Intl856 843 1.6%2.5%-0.9%3,470 3,417 1.5%3.0%-1.5%WW2,315 2,268 2.1%2.5%-0.4%9,158 8,942 2.4%3.0%-0.6%HIPSUS272 266 2.5%2.5%-1,057 996 6.2%6.2%-Intl146 132 10.6%11.7%-1.1%581 564 3.0%4.6

62、%-1.6%WW418 398 5.2%5.6%-0.4%1,638 1,560 5.0%5.6%-0.6%KNEESUS238 242 -1.5%-1.5%-922 896 2.9%2.9%-Intl160 144 10.7%11.3%-0.6%623 559 11.3%12.4%-1.1%WW398 387 3.1%3.3%-0.2%1,545 1,456 6.1%6.5%-0.4%TRAUMAUS514 487 5.5%5.5%-2,013 1,949 3.3%3.3%-Intl250 255 -1.9%-0.5%-1.4%1,036 1,030 0.6%2.1%-1.5%WW764 7

63、41 3.0%3.5%-0.5%3,049 2,979 2.3%2.9%-0.6%SPINE,SPORTS&OTHERUS434 430 1.1%1.1%-1,696 1,684 0.7%0.7%-Intl300 311 -3.6%-2.9%-0.7%1,230 1,263 -2.6%-1.2%-1.4%WW735 742 -0.9%-0.6%-0.3%2,926 2,947 -0.7%-0.1%-0.6%Change%ChangeREPORTED SALES vs.PRIOR PERIOD($MM)REPORTED SALES vs.PRIOR PERIOD($MM)FOURTH QUART

64、ERTWELVE MONTHS20242023ReportedOperational(1)Currency20242023ReportedOperational(1)CurrencySURGERYUS1,038 1,047 -0.9%-0.9%-4,003 4,031 -0.7%-0.7%-Intl1,469 1,484 -1.0%1.4%-2.4%5,842 6,006 -2.7%0.6%-3.3%WW2,507 2,530 -0.9%0.4%-1.3%9,845 10,037 -1.9%0.1%-2.0%ADVANCEDUS478 468 2.0%2.0%-1,838 1,833 0.2%

65、0.2%-Intl673 698 -3.6%-1.6%-2.0%2,650 2,837 -6.6%-3.5%-3.1%WW1,151 1,167 -1.4%-0.1%-1.3%4,488 4,671 -3.9%-2.0%-1.9%GENERALUS560 579 -3.1%-3.1%-2,165 2,198 -1.5%-1.5%-Intl795 785 1.4%4.0%-2.6%3,192 3,168 0.8%4.3%-3.5%WW1,357 1,364 -0.5%1.0%-1.5%5,358 5,366 -0.2%2.0%-2.2%VISIONUS509 487 4.5%4.5%-2,128

66、 2,086 2.0%2.0%-Intl794 721 10.2%12.2%-2.0%3,018 2,986 1.1%3.7%-2.6%WW1,303 1,208 7.9%9.1%-1.2%5,146 5,072 1.5%3.0%-1.5%CONTACT LENSES/OTHERUS396 374 6.0%6.0%-1,684 1,626 3.6%3.6%-Intl541 508 6.4%8.5%-2.1%2,049 2,076 -1.3%1.8%-3.1%WW937 882 6.3%7.4%-1.1%3,733 3,702 0.8%2.6%-1.8%SURGICALUS113 114 -0.

67、4%-0.4%-444 460 -3.4%-3.4%-Intl252 212 19.3%21.1%-1.8%969 910 6.5%8.2%-1.7%WW365 326 12.4%13.6%-1.2%1,413 1,370 3.2%4.3%-1.1%TOTAL MEDTECHUS4,227 3,930 7.6%7.6%-16,332 15,275 6.9%6.9%-Intl3,961 3,743 5.8%7.6%-1.8%15,525 15,125 2.6%5.4%-2.8%WW8,188$7,673$6.7%7.6%-0.9%31,857$30,400 4.8%6.2%-1.4%*Perce

68、ntage greater than 100%or not meaningful(1)Operational growth excludes the effect of translational currency(2)Unaudited(3)Reported as U.S.sales(4)Previously referred to as Interventional Solutions(5)Acquired on May 31,2024%ChangeNote:Columns and rows within tables may not add due to rounding.Percent

69、ages have been calculated using actual,non-rounded figures and,therefore,may not recalculate precisely%Change20242023TotalOperationsCurrency20242023TotalOperationsCurrencyInnovative MedicineU.S.8,977$8,079 11.1 11.1 -33,970$31,169 9.0 9.0 -International5,355 5,643 (5.1)(1.0)(4.1)22,994 23,590 (2.5)1

70、.3 (3.8)Worldwide14,332 13,722 4.4 6.1 (1.7)56,964 54,759 4.0 5.7 (1.7)COVID-19 VaccineU.S.-International-44 *198 1,117 (82.4)(82.4)0.0 Worldwide-44 *198 1,117 (82.4)(82.4)0.0 Innovative Medicine excluding COVID-19 VaccineU.S.8,977 8,079 11.1 11.1 -33,970 31,169 9.0 9.0 -International5,355 5,599 (4.

71、4)(0.3)(4.1)22,796 22,473 1.4 5.5 (4.1)Worldwide14,332 13,678 4.8 6.5 (1.7)56,766 53,642 5.8 7.5 (1.7)WorldwideU.S.13,204 12,009 10.0 10.0 -50,302 46,444 8.3 8.3 -International9,316 9,386 (0.7)2.5 (3.2)38,519 38,715 (0.5)2.9 (3.4)Worldwide22,520 21,395 5.3 6.7 (1.4)88,821 85,159 4.3 5.9 (1.6)COVID-1

72、9 VaccineU.S.-International-44 *198 1,117 (82.4)(82.4)0.0 Worldwide-44 *198 1,117 (82.4)(82.4)0.0 WorldwideU.S.13,204 12,009 10.0 10.0 -50,302 46,444 8.3 8.3 -International9,316 9,342 (0.3)2.9 (3.2)38,321 37,598 1.9 5.5 (3.6)Worldwide excluding COVID-19 Vaccine22,520$21,351 5.5 6.9 (1.4)88,623$84,04

73、2 5.5 7.0 (1.5)Europe 4,921$4,962 (0.8)(0.2)(0.6)20,212$20,410 (1.0)(0.6)(0.4)Europe COVID-19 Vaccine Sales-44 *198 1,117 (82.4)(82.4)0.0 Europe excluding COVID-19 Vaccine Sales4,921$4,918 0.1 0.7 (0.6)20,014$19,293 3.7 4.1 (0.4)*Percentage greater than 100%or not meaningfulPercent ChangeFOURTH QUAR

74、TERPercent ChangeSupplemental Sales Information(Unaudited)(Dollars in Millions)TWELVE MONTHSJohnson&Johnson and SubsidiariesReconciliation of Non-GAAP Financial Measures20242023202420232024202320242023Reported Income Before Tax by Segment From Continuing Operations$4,009 4,238 72 404 (194)184 3,887

75、4,826%to Sales28.0%30.9%0.9%5.3%-0.9%0.9%17.3%22.6%Intangible asset amortization expense685 747 486 401 -1,171 1,148 In-process research and development impairments17 -58 -17 58 Litigation related(41)17 (29)149 54 -(16)166 Loss/(gain)on securities(50)(112)(18)(59)-(264)(68)(435)Restructuring related

76、2 55 60 84 -62 139 Acquisition,integration and divestiture related12 175 268 62 18 -298 237 Medical Device Regulation-47 88 -47 88 COVID-19 Vaccine related costs23 10 -23 10 Adjusted Income Before Tax by Segment From Continuing Operations$4,657 5,130 886 1,187 (122)(80)5,421 6,237%to Sales32.5%37.4%

77、10.8%15.5%-0.5%-0.4%24.1%29.2%*Estimated as of 1/22/2025 As Reported Research and development expense*$3,698 3,357 1,600 1,123 5,298 4,480%to Sales25.8%24.5%19.5%14.6%23.5%20.9%*Includes the following Acquired IPR&D:Laminar-Q4 2023390 390V-Wave-Q4 2024540540 Total 540390540 390Q4 QTD-Income Before T

78、ax*and Research&Development Expense by SegmentDollars in MillionsInnovative MedicineMedTechUnallocatedWorldwide TotalJohnson&Johnson and SubsidiariesReconciliation of Non-GAAP Financial Measures20242023202420232024202320242023Reported Income Before Tax by Segment From Continuing Operations$18,919 18

79、,246 3,740 4,669 (5,972)(7,853)16,687 15,062%to Sales33.2%33.3%11.7%15.4%-6.7%-9.2%18.8%17.7%Intangible asset amortization expense2,772 2,983 1,754 1,549 -4,526 4,532 In-process research and development impairments211 206 -107 -211 313 Litigation related358 (108)(14)190 5,106 7,070 5,450 7,152 Loss/

80、(gain)on securities(76)362 30 (102)352 381 306 641 Restructuring related102 479 167 319 -269 798 Acquisition,integration and divestiture related66 175 1,015 164 145 -1,226 339 Medical Device Regulation-204 311 -204 311 COVID-19 Vaccine related costs100 663 -100 663 Adjusted Income Before Tax by Segm

81、ent From Continuing Operations$22,452 23,006 6,896 7,207 (369)(402)28,979 29,811%to Sales39.4%42.0%21.6%23.7%-0.4%-0.5%32.6%35.0%*Estimated as of 1/22/2025 As Reported Research and development expense*$13,529 11,963 3,703 3,122 17,232 15,085%to Sales23.8%21.8%11.6%10.3%19.4%17.7%*Includes the follow

82、ing Acquired IPR&D:Laminar-Q4 2023390 390Yellow Jersey(NM26 bispecific antibody)-Q3 20241,250 1,250 V-Wave-Q4 2024540 540 Total1,250 540 390 1,790 390 Q4 YTD-Income Before Tax*and Research&Development Expense by SegmentDollars in MillionsInnovative MedicineMedTechUnallocatedWorldwide Total Fourth Qu

83、arter Dec.29,2024GAAPIntangible asset amortizationLitigation relatedRestructuring relatedMedical Device RegulationFourth Quarter Dec.29,2024Non-GAAPCost of products sold7,128$(1,162)(20)(153)(18)-5,775 Selling,marketing and admin expenses6,453 (4)6,449 Research and development expense5,298 -(25)(6)5

84、,267 Other(Income)/Expense(161)(9)16 -(145)68 (17)(248)In-process research and development impairments17 (17)-Restructuring42 (42)-Provision for taxes on income456 171 (158)4 3 80 (34)9 5 (61)475 Net Earnings from Continuing Operations3,431 1,000 142 13 59 218 (34)38 18 61 4,946 Fourth Quarter Dec.3

85、1,2023 GAAPIntangible asset amortizationLitigation relatedRestructuring relatedMedical Device RegulationFourth Quarter Dec.31,2023Non-GAAPCost of products sold6,798$(1,131)(83)(42)(12)-5,530 Selling,marketing and admin expenses5,810 (8)5,802 Research and development expense4,480 (16)(38)(1)4,425 Oth

86、er(Income)/Expense(421)(17)(166)-(221)435 3 (387)In-process research and development impairments58 (58)-Restructuring56 (56)-Provision for taxes on income694 175 (134)13 16 30 (191)16 -56 675 Net Earnings from Continuing Operations4,132 973 300 45 123 207 (244)72 10 (56)5,562 Twelve Months Dec.29,20

87、24GAAPIntangible asset amortizationLitigation relatedRestructuring relatedMedical Device RegulationTwelve Months Dec.29,2024Non-GAAPCost of products sold27,471$(4,517)(35)(359)(84)(8)22,468 Selling,marketing and admin expenses22,869 (16)-22,853 Research and development expense17,232 (69)(104)(25)17,

88、034 Other(Income)/Expense4,694 (9)(5,450)-(798)(306)(67)(1,936)In-process research and development impairments211 (211)-Restructuring234 (234)-Provision for taxes on income2,621 644 1,066 47 45 302 (29)38 22 (19)4,737 Net Earnings from Continuing Operations14,066 3,882 4,384 164 224 924 335 166 78 1

89、9 24,242 Twelve Months Dec.31,2023GAAPIntangible asset amortizationLitigation relatedRestructuring relatedMedical Device RegulationTwelve Months Dec.31,2023Non-GAAPCost of products sold26,553$(4,511)(309)(133)(189)21,411 Selling,marketing and admin expenses21,512 (29)21,483 Research and development

90、expense15,085 (32)(149)(99)14,805 Other(Income)/Expense6,634 (21)(7,152)-(307)(641)(375)(1,862)In-process research and development impairments313 (313)-Restructuring489 (489)-Provision for taxes on income1,736 707 1,505 70 157 52 (9)57 155 (28)4,402 Net Earnings from Continuing Operations13,326 3,82

91、5 5,647 243 641 287 650 254 508 28 25,409 In-process research and development impairmentsAcquisition,integration and divestiture related(Loss)/gain on securitiesCOVID-19 Vaccine Related CostsTax legislation and other tax relatedIn-process research and development impairmentsAcquisition,integration a

92、nd divestiture related(Loss)/gain on securitiesCOVID-19 Vaccine Related CostsTax legislation and other tax relatedYear to DateJohnson&Johnson and SubsidiariesGAAP to Non-GAAP Reconciliation$in MillionsQuarter to DateIn-process research and development impairmentsAcquisition,integration and divestiture related(Loss)/gain on securitiesCOVID-19 Vaccine Related CostsTax legislation and other tax relatedIn-process research and development impairmentsAcquisition,integration and divestiture related(Loss)/gain on securitiesCOVID-19 Vaccine Related CostsTax legislation and other tax related